June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
AREDS Supplementation and Complement System Levels in Patients with Intermediate Age-Related Macular Degeneration
Author Affiliations & Notes
  • Itzam Marin
    Ophthalmology, University of Colorado Denver School of Medicine, Aurora, Colorado, United States
    Sue Anschutz-Rodgers Eye Center, University of Colorado Denver School of Medicine, Aurora, Colorado, United States
  • Brandie D. Wagner
    University of Colorado School of Public Health Department of Biostatistics & Informatics, Aurora, Colorado, United States
    Sue Anschutz-Rodgers Eye Center, University of Colorado Denver School of Medicine, Aurora, Colorado, United States
  • Niranjan Manoharan
    Ophthalmology, University of Colorado Denver School of Medicine, Aurora, Colorado, United States
    Sue Anschutz-Rodgers Eye Center, University of Colorado Denver School of Medicine, Aurora, Colorado, United States
  • Alan Palestine
    Ophthalmology, University of Colorado Denver School of Medicine, Aurora, Colorado, United States
    Sue Anschutz-Rodgers Eye Center, University of Colorado Denver School of Medicine, Aurora, Colorado, United States
  • Felix Poppelaars
    Nephrology, University of Colorado Denver School of Medicine, Aurora, Colorado, United States
  • Jennifer L. Patnaik
    Ophthalmology, University of Colorado Denver School of Medicine, Aurora, Colorado, United States
    Sue Anschutz-Rodgers Eye Center, University of Colorado Denver School of Medicine, Aurora, Colorado, United States
  • Michael Holers
    Immunology, University of Colorado Denver School of Medicine, Aurora, Colorado, United States
  • Ashley Frazer-Abel
    Exera BioLabs, University of Colorado Denver School of Medicine, Aurora, Colorado, United States
  • Marc Mathias
    Ophthalmology, University of Colorado Denver School of Medicine, Aurora, Colorado, United States
    Sue Anschutz-Rodgers Eye Center, University of Colorado Denver School of Medicine, Aurora, Colorado, United States
  • Naresh Mandava
    Ophthalmology, University of Colorado Denver School of Medicine, Aurora, Colorado, United States
    Sue Anschutz-Rodgers Eye Center, University of Colorado Denver School of Medicine, Aurora, Colorado, United States
  • Anne M. Lynch
    Ophthalmology, University of Colorado Denver School of Medicine, Aurora, Colorado, United States
    Sue Anschutz-Rodgers Eye Center, University of Colorado Denver School of Medicine, Aurora, Colorado, United States
  • Footnotes
    Commercial Relationships   Itzam Marin None; Brandie Wagner None; Niranjan Manoharan None; Alan Palestine None; Felix Poppelaars None; Jennifer Patnaik None; Michael Holers None; Ashley Frazer-Abel None; Marc Mathias None; Naresh Mandava None; Anne Lynch None
  • Footnotes
    Support  National Eye Institute of the NIH 32456 (AML), a Research to Prevent Blindness grant to the Department of Ophthalmology, University of Colorado, the Frederic C. Hamilton Macular Degeneration Center, Sue Anschutz-Rogers Eye Center Research Fund, and by NIH/NCATS Colorado CTSA Grant Number UL1 TR002535.
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 2531 – A0100. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Itzam Marin, Brandie D. Wagner, Niranjan Manoharan, Alan Palestine, Felix Poppelaars, Jennifer L. Patnaik, Michael Holers, Ashley Frazer-Abel, Marc Mathias, Naresh Mandava, Anne M. Lynch; AREDS Supplementation and Complement System Levels in Patients with Intermediate Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2022;63(7):2531 – A0100.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Age-related macular degeneration (AMD) is a degenerative disease of the retina which can be classified into early, intermediate, and advanced phenotypes. It is recognized that the complement system plays a key role in the pathogenesis of AMD. While advances have been made in the treatment of wet AMD, the only approved therapy for dry AMD to date is AREDS supplementation. There is a paucity of research on the mechanisms behind the effectiveness of AREDS supplementation in reducing the risk of AMD progression. Given the important prognostic and therapeutic value of the intermediate phenotype of AMD (iAMD), the goal of this study was to determine if there was a difference in complement factors among patients with iAMD taking AREDS supplementation compared to those with iAMD not taking AREDS supplementation

Methods : Patients with iAMD were drawn from a biorepository registry of patients with AMD. The diagnosis of iAMD was confirmed with multimodal imaging. Plasma complement factor levels were measured by ELISA and multiplex Luminex immunoassays. Non-parametric Wilcoxon tests were used to compare levels for each analyte by AREDS supplementation

Results : We identified 211 patients with iAMD, of which 92 were on AREDS supplementation at time of study enrollment and 119 were not. The results for all the complement factors measured are shown in Table 1. We found lower levels of C3 (p=0.05) and C5a (p<0.01) in patients taking AREDS supplementation compared to those not on AREDS supplementation. There were no differences between the groups for the other complement factors measured

Conclusions : We demonstrate significant differences in two important components of the complement system including complement factor C3 and the activation fragment C5a in patients with iAMD taking AREDS supplementation compared to patients not taking AREDS. Our results suggest that further studies are needed in a larger cohort of patient with iAMD to establish the relationship of complement system activity and AREDS supplementation. These results can shed light on the mechanism of action of AREDS supplementation and the reason for reducing risk of progression to advanced AMD forms

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

 

Table 1: Median and interquartile range (IQR) for each analyte across AREDS supplement groups with iAMD.

Table 1: Median and interquartile range (IQR) for each analyte across AREDS supplement groups with iAMD.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×